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ABSTRACT
Objectives: Recent studies have demonstrated that disorders of bone metabolism, which is regulated by RANK/RANKL/OPG 
signaling pathway, are the cause of osteoporosis. The aim of the study was to investigate the distribution of genotypes of 
the RANK 575C>T and RANKL –643C>T polymorphisms and to analyze their relationship with bone parameters in post-
menopausal women.
Material and methods: A total of 310 postmenopausal Caucasian women (139 with osteoporosis, 107 with osteopenia, and 
64 healthy postmenopausal controls) were included. Bone mineral density (BMD) at the lumbar region of the spine (L2–L4) 
was measured by dual energy X-ray absorptiometry (DXA). Genetic analysis was performed using the PCR-RFLP method.
Results: Analysis of the frequency of genotypes and alleles of the RANK 575C>T and RANKL –643C>T polymorphisms did not 
show any statistically significant differences between the study groups (osteoporosis and osteopenia) and postmenopausal 
women with normal t-score value (ns). Notably, a significant association between the RANKL –643C>T polymorphism and 
body mass, such as BMI values in osteoporotic women (p<0.05), was observed.
Conclusions: Our results suggest lack of association between the 575C>T RANK polymorphism and the development of 
osteoporosis. The –643C>T RANKL polymorphism, through its significant influence on body weight and BMI value, may 
contribute to the development of osteoporosis in postmenopausal women.
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INTRODUCTION
Osteoporosis is a serious metabolic disorder of old age, 
characterized by decreased bone mineral density. Osteopo-
rosis is a complex disease and numerous studies have dem-
onstrated that hormonal, environmental, and genetic factors 
play a significant role in its etiology [1–4]. Osteoporosis is 
a vital problem among elderly populations. Disturbances in 
bone microarchitecture metabolism often lead to bone frac-
tures, restricted mobility, and death, making osteoporosis 
a medical as well as socio-economical problem [5, 6]. Thus, 
numerous etiological studies are focused on factors involved 
in the regulation of bone mineralization. Several of these 
factors are involved in the process of impaired osteoclastic 
activity and increased bone resorption. Their observations 
highlight the significance of the contribution of genetic 
polymorphisms to osteoclastic activity [7, 8].
In recent years, it has been noted that the processes of 
growth, maturity, segregation and differentiation of osteo-
clasts are synchronized and modulated by various factors, 
with the signal pathway, which is directly involved in bone 
resorption, playing the key role [9, 10]. Currently, it is be-
lieved that the receptor activator of nuclear factor kappa B 
(RANK), its ligand (RANKL — receptor activator of nuclear 
factor-κB ligand) and osteoprotegerin (OPG) are involved 
in this trail [9, 10]. The abovementioned factors belong to 
the tumor necrosis factor (TNF) family. It seems that dy-
namic steadiness between RANKL/RANK and OPG activities 
determines regulation of differentiation and activation of 
osteoclasts, significantly affecting bone tissue metabolism. 
The RANKL/RANK/OPG trail is directly involved in prolifera-
tion and apoptosis of osteoclasts. The disturbances in the 
RANKL/RANK/OPG system can be a major part of the etiol-
ogy of postmenopausal osteoporosis. Moreover, it has been 
shown that genes encoding RANKL/RANK/OPG system are 
closely involved in the development of osteoporosis [10, 11].
The RANKL protein is the key factor for separation and 
demarcation of osteoclasts, responsible for their enrolment, 
fusion into multinuclear osteoclasts, and activation of the 
mature forms. Another major function of RANKL is the inhibi-
tion of osteoclast apoptosis [11]. The transmembrane RANK 
protein is the receptor of RANKL. Results of the RANK/RANKL 
fusion include differentiation of preosteoclasts into mature 
forms, increase of osteoclasts activity, and inhibition of os-
teoclastic apoptosis [9]. The third factor in the described 
pathway is osteoprotegerin, a dimeric, soluble cytokine pro-
duced in the activated osteoblasts. OPG is a ‘receptor-trap’ 
for RANKL and, in consequence, inhibits the entire trail of 
osteoclast differentiation at the early stages. In this mecha-
nism, OPG is proposed to play the role of a bone resorption 
inhibitor, as well as the factor of bone mass regulating. OPG 
suppresses osteoclast differentiation, blocks their activity, 
and induces osteoclast apoptosis [12]. The most important 
function of OPG is reduction of the number of active osteo-
clasts and, through this process, inhibition of bone resorp-
tion. Some genetic polymorphisms in the RANKL/RANK/OPG 
signal trail have been determined. Several polymorphic vari-
ants of these genes have been postulated to be connected 
with osteoporosis in postmenopausal women [13–17].
The aim of the study was to examine the frequency 
of alleles and genotypes of the RANK 575C>T and RANKL 
–643C>T polymorphisms in a group of postmenopausal 
women and to determine the association of the examined 
genetic variants with parameters of bone turnover and 
progression of osteoporosis.
MATERIAL AND METHODS
The study (conducted between 2004–2006) included 
310 postmenopausal Caucasian women (54.5 ± 8.5 years). 
The patients were classified into three subgroups with re-
gard to the value of the rate t-score: 139 with osteoporosis 
(t-score < –2.5, 56.1 ± 8.8 years), 107 with osteopenia (t-score 
between 2.5 and –1, 53.3 ± 8.1 years), and 64 healthy post-
menopausal controls (t-score > –1, 53.4 ± 8.2 years of age). 
Menopause onset at least one year before the study consti-
tuted an eligibility criterion. The exclusion criteria were as 
follows: history of double-sided ovariectomy, medications 
which might influence bone metabolism (hormone therapy, 
selective modulators of estrogen receptors, thyrocalcitonin, 
bisphosphonates, thyroid hormones, steroids, heparin, an-
ticonvulsant medications, GnRH analogues, tibolone), and 
history of diseases affecting bone density and loss of bone 
mass (endocrine and metabolic disorders, hematological 
diseases, cancers, nephropathies and autoimmune diseas-
es). On the basis of densitometry tests (DXA — dual energy 
X-ray absorptiometry, LUNAR DPX 100 apparatus, Lunar 
Corp., Madison, USA), the following parameters describ-
ing the state of bone tissue were evaluated: bone mineral 
density (BMD) in the lumbar region of the spine (L2–L4), 
as well as the rates: t-score and z-score. Rates of medium 
bone mineral density were also evaluated in comparison to 
the average for young adults (YA — young adults) and the 
average bone mineral density in comparison to the average 
for the given age (AM — age matched). Additionally, body 
mass index (BMI) was determined on the basis of body 
weight and height measurements. Local Ethics Committee 
approved of the study (1426/04). All women gave their 
written informed consent.
The RANK 575C>T and RANKL –643C>T polymorphisms 
were determined by polymerase chain reaction/restriction 
fragment length polymorphism (PCR/RFLP) analysis. For the 
analysis of the RANK 575C>T and RANKL –643C>T polymor-
phisms, the following primers were used: RANK-forward: 
5’- CAT CAT GGG ACA GAG AAA TCC GAC G -3’, RANK-reverse: 
5’- GAG AAT GAA ATA TTC AGC TGA CC -3’, RANKL: 5’- GGA 
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TGC TTG CTT CTG GCT AC -3’, RANKL: 5’- ACC CTT CCT GTC 
CAA CCT CT -3’. The polymorphic sites were defined using 
restriction enzymes for the RANK gene, such as BstUI and 
TscAI for RANKL. Products of the electrophoresis were evalu-
ated using visualization with UV light, using the system of 
documentation and computer analysis of the UVI image (KS 
4000/Image PC of the Syngen Biotech Molecular Biology 
Instruments company).
SPSS 17.0 PL software was used for statistical analysis 
of the results of the frequency of genotypes and alleles of 
the examined polymorphisms. The prevalence of certain 
genotypes was compared with the expected values using 
the chi-square test. The analysis of the clinical and biochemi-
cal parameters and their relationship with the previously 
reported polymorphisms was performed using one-way 
ANOVA test (SPSS Inc.). The p-value of < 0.05 was considered 
as statistically significant.
RESULTS
Analysis of the frequency of genotypes and alleles of the 
RANK 575C>T and RANKL –643C>T polymorphisms did not 
show any statistically significant differences between the 
study groups (osteoporosis and osteopenia) as compared 
to postmenopausal women with normal t-score values (ns) 
(Table 1).
Moreover, average parameters of bone turnover for 
each genotype of the examined RANK 575C>T and RANKL 
–643C>T polymorphisms have been also compared be-
tween the investigated subgroups. No significant corre-
lations between the majority of the parameters of bone 
turnover and frequency of particular genotypes in women 
with osteoporosis, osteopenia and postmenopausal women 
with normal t-score values have been observed (Table 2). 
Noteworthy, a significant association between the RANKL 
–643C>T polymorphism and body mass, such as BMI values 
in osteoporotic women, was observed (p < 0.05) (Table 2).
DISCUSSION
Diagnostic testing for the presence of genetic polymor-
phisms, or their influence on the values of parameters deter-
mining the state of bone tissue in women after menopause, 
is essential to understand the pathomechanism of osteo-
porosis. The exact effect of the RANKL –643C>T and RANK 
575C>T polymorphisms on bone mineral density remains 
vague. Assessment of the impact of OPG gene polymor-
phisms on bone turnover parameters is also essential. Many 
studies focus on the correlation of the RANK/RANKL/OPG 
signaling pathway polymorphisms with bone mineral den-
sity and other parameters [13, 16, 18].
In our recent study, we analyzed the significance of 
–163 A>G, –254T>G, –950T>C and 1181G>C polymorphisms 
in the development of osteoporosis. No statistically signifi-
cant differences in the examined subgroups of women with 
osteoporosis, osteopenia and correct values of t-score have 
been shown [17].
The present study, performed in a large population of 
Polish women, also did not show any correlation between 
the investigated polymorphisms and BMD values. We in-
vestigated other polymorphism in the RANK/RANKL/OPG 
signaling pathway in connection with the pathomechanism 
Table 1. Frequency of genotypes and alleles of RANK and RANKL polymorphisms in women with osteopenia, osteoporosis and normal t-score values
Osteoporosis
n = 139
Osteopenia
n = 107
Normal t-score value
n = 64
Observed
n (%)
Expected
(%)
Observed
n (%)
Expected
(%)
Observed
n (%)
Expected
(%)
RANK
575C>T
CC 47 (33.8) 33.5 22 (20.6) 23.6 17 (26.6) 26.6
CT 67 (48.2) 48.8 60 (56.1) 50.0 32 (50.0) 49.9
TT 25 (18.0) 17.7 25 (23.4) 26.4 15 (23.4) 23.4
Allele
C 161 (57.9) – 104 (48.6) – 66 (51.6) –
T 117 (42.1) – 110 (51.4) – 62 (48.4) –
Genotype
RANKL
–643C>T
CC 33 (23.7) 26.4 20 (18.7) 21.8 13 (20.3) 24.2
CT 77 (55.4) 49.9 60 (56.1) 49.8 37 (57,8) 50.0
TT 29 (20.9) 23.6 27 (25.3) 28.4 14 (21.9) 25.8
Allele
C 143 (51.4) – 100 (46.7) – 63 (49.2) –
T 135 (48.6) – 114 (53.3) – 65 (50.8) –
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of osteoporosis. The genotype frequency of RANKL –643C>T 
and RANK 575C>T polymorphisms was similar to the distri-
bution of genotypes in other Caucasian populations [19–21]. 
Analysis of both investigated RANKL/RANK polymorphisms 
revealed no significant association between particular geno-
types and osteoporosis, or development of osteopenia. 
Additionally, for the RANKL –643C>T and RANK 575C>T poly-
morphisms, no statistically significant correlations between 
the studied genotypes, development of osteoporosis, and 
bone parameters such as t-score, z-score, L2–L4 BMD YA% 
or L2–L4 BMD AM% were noted in all groups of women. 
Interestingly, for the RANKL –643C>T polymorphism we 
showed a statistically significant relationship between the 
CC genotype and lower body weight and BMI.
Similar results to our findings were reported in a study 
of postmenopausal women in Slovenia, which also con-
firmed no relationship between bone mineral density in 
the lumbar spine and hip BMD and the –643C>T polymor-
phism. However, higher BMD values in the femur neck were 
noted in TT genotype carriers as compared to CC carriers 
[19]. There were no statistically significant differences be-
tween genotype frequency in the group of healthy women 
and women with osteoporosis. A significant correlation 
between all genotypes and bone mineral density in the 
lumbar spine (p = 0.041) has been demonstrated in the 
group of women with osteoporosis, whereas there was no 
association between genotypes and BMD of the femoral 
neck (BMD-fn) and total femur BMD (BMD-th). The analysis 
of healthy women showed no relationship between the 
particular genotypes of the –643C>T polymorphism and 
bone mineral density in the lumbar spine (BMD-ls), bone 
mineral density of the femoral neck (BMD-fn), and total 
femoral bone mineral density (BMD-th) [20].
Distribution of the RANK 575C>T polymorphism differs in 
the investigated populations and the results obtained among 
Polish women were significantly different as compared to 
Korean or Chinese populations. The influence of the RANK 
575C>T polymorphism on bone parameters remains unclear. 
Results referring to the Polish population also have shown 
that the RANK 575C>T polymorphism did not seem to be a ge-
netic factor associated with BMD of the lumbar spine, similarly 
to Korean postmenopausal women [22]. A study conducted 
in an Asian population of postmenopausal women showed 
that the 575C>T RANK polymorphism is not associated with 
BMD of the lumbar spine and femoral neck [22–24].
In a Chinese population, patients with low BMD were 
compared to individuals with high BMD to show a link be-
tween the evaluated polymorphisms and BMD [25]. Studies 
of the Chinese population demonstrated the relations of one 
of the RANK polymorphisms with BMD of the lumbar spine 
and hip joint [26]. The same authors showed that the RANK 
and RANKL genes were associated with age of first menarche 
as well as age at natural menopause in Caucasian females 
in the United States [26].
Despite numerous genetic analyses, contribution of the 
polymorphic variants to the development of osteoporosis 
remains unclear. Studies evaluating a possible correlation 
between the RANK and RANKL polymorphisms and bone 
mineral density as well as the development of osteoporosis 
also offered no conclusive results. Thus, large, multi-center 
studies are necessary to assess the distribution of the RANKL 
and RANK polymorphic variants in Caucasian populations.
CONCLUSIONS
Our results suggest lack of a association between the 
575C>T RANK polymorphism and the development of os-
teoporosis, whereas the –643C>T RANKL polymorphism, 
due to its significant influence on body weight and BMI 
values in postmenopausal women, could contribute to the 
development of osteoporosis.
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